Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at the dose of 10 mg/d. Clinical CR was achieved in nine of 10 (90%) patients treated with As2O3 alone and in the remaining five patients treated by the combination of As2O3 and low-dose chemotherapeutic drugs or ATRA. During the treatment with As2O3, there was no bone marrow depression and only limited side effects were encountered. Pharmacokinetic studies, which were performed in eight patients, showed that after a peak level of 5.54 micromol/L to 7.30 micromol/L, plasma arsenic was rapidly eliminated, and the continuous administration of As2O3 did not alter its pharmacokinetic behaviors. In addition, increased amounts of arsenic appeared in the urine, with a daily excretion accounting for approximately 1% to 8% of the total daily dose administered. Arsenic contents in hair and nail were increased, and the peak content of arsenic could reach 2.5 to 2.7 microg/g tissue at CR. On the other hand, a decline of the arsenic content in hair and nail was observed after withdrawal of the drug. We conclude that As2O3 treatment is an effective and relatively safe drug in APL patients refractory to ATRA and conventional chemotherapy.
Shen
Z X
ZX
Shanghai Institute of Hematology, Department of Hematology, Rui-Jin Hospital, P.R. China.
Chen
G Q
GQ
Ni
J H
JH
Li
X S
XS
Xiong
S M
SM
Qiu
Q Y
QY
Zhu
J
J
Tang
W
W
Sun
G L
GL
Yang
K Q
KQ
Chen
Y
Y
Zhou
L
L
Fang
Z W
ZW
Wang
Y T
YT
Ma
J
J
Zhang
P
P
Zhang
T D
TD
Chen
S J
SJ
Chen
Z
Z
Wang
Z Y
ZY
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D010087:Oxides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis; D012008:Recurrence; D012074:Remission Induction; D000072482:Retinoic Acid Receptor alpha; D015996:Survival Rate; D013997:Time Factors
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D000077237:Arsenic Trioxide